218 related articles for article (PubMed ID: 34838486)
1. [Angiogenesis inhibitors: mechanism of action and nephrotoxicity].
Clou E; Luque Y
Nephrol Ther; 2022 Feb; 18(1):1-6. PubMed ID: 34838486
[TBL] [Abstract][Full Text] [Related]
2. [Nephrotoxicity of anti-angiogenesis drugs].
Grechukhina KS; Chebotareva NV; Krasnova TN
Ter Arkh; 2020 Jul; 92(6):93-98. PubMed ID: 33346501
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
[TBL] [Abstract][Full Text] [Related]
4. Renal effects of anti-angiogenesis therapy: update for the internist.
Gurevich F; Perazella MA
Am J Med; 2009 Apr; 122(4):322-8. PubMed ID: 19332223
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
Teoh D; Secord AA
Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
[TBL] [Abstract][Full Text] [Related]
6. Anti-Angiogenic Drugs, Vascular Toxicity and Thromboembolism in Solid Cancer.
Riondino S; Del Monte G; Fratangeli F; Guadagni F; Roselli M; Ferroni P
Cardiovasc Hematol Agents Med Chem; 2017; 15(1):3-16. PubMed ID: 28137223
[TBL] [Abstract][Full Text] [Related]
7. Hypertension and proteinuria: a class-effect of antiangiogenic therapies.
Launay-Vacher V; Deray G
Anticancer Drugs; 2009 Jan; 20(1):81-2. PubMed ID: 19343005
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Hsu JY; Wakelee HA
BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
[TBL] [Abstract][Full Text] [Related]
9. Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients.
Kurzrock R; Stewart DJ
Clin Cancer Res; 2017 Mar; 23(5):1137-1148. PubMed ID: 27940520
[TBL] [Abstract][Full Text] [Related]
10. Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence.
Hanna RM; Barsoum M; Arman F; Selamet U; Hasnain H; Kurtz I
Kidney Int; 2019 Sep; 96(3):572-580. PubMed ID: 31229276
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
[TBL] [Abstract][Full Text] [Related]
12. Targeting angiogenesis in esophagogastric adenocarcinoma.
Okines AF; Reynolds AR; Cunningham D
Oncologist; 2011; 16(6):844-58. PubMed ID: 21632459
[TBL] [Abstract][Full Text] [Related]
13. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
Grothey A; Ellis LM
Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
[TBL] [Abstract][Full Text] [Related]
14. [Angiogenesis inhibitor therapies: focus on hypertension and kidney toxicity].
Izzedine H
Bull Cancer; 2007 Nov; 94(11):981-6. PubMed ID: 18055316
[TBL] [Abstract][Full Text] [Related]
15. A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab.
Butler CT; Reynolds AL; Tosetto M; Dillon ET; Guiry PJ; Cagney G; O'Sullivan J; Kennedy BN
J Biol Chem; 2017 Mar; 292(9):3552-3567. PubMed ID: 28035003
[TBL] [Abstract][Full Text] [Related]
16. [Renal toxicity of anti-VEGF (corrected) targeted therapies].
Vigneau C; Rioux-Leclercq N
Nephrol Ther; 2013 Jun; 9(3):174-9. PubMed ID: 23410950
[TBL] [Abstract][Full Text] [Related]
17. VEGF inhibition and renal thrombotic microangiopathy.
Eremina V; Jefferson JA; Kowalewska J; Hochster H; Haas M; Weisstuch J; Richardson C; Kopp JB; Kabir MG; Backx PH; Gerber HP; Ferrara N; Barisoni L; Alpers CE; Quaggin SE
N Engl J Med; 2008 Mar; 358(11):1129-36. PubMed ID: 18337603
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.
Shinkaruk S; Bayle M; Laïn G; Déléris G
Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):95-117. PubMed ID: 12678905
[TBL] [Abstract][Full Text] [Related]
20. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review.
Eskens FA; Verweij J
Eur J Cancer; 2006 Dec; 42(18):3127-39. PubMed ID: 17098419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]